LABT Stock Price, Chart, Stats & News

Lakewood-Amedex Biotherapeutics, Inc.
Save
Lakewood-Amedex Biotherapeutics, Inc. (LABT) does not currently pay a dividend.
2.92M
Market cap
–
Current P/E
–
Forward P/E
LABT chart
About
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial.
Similar securities
Based on sector and market capitalization
Report issue





